A STUDY TO EVALUATE AND COMPARE THE EFFICACY AND SAFETY OF TOPICAL CYCLOSPORINE-A 0.5% WITH TOPICAL PLACEBO (ARTIFICIAL TEARS) IN ALLEVIATING THE CLINICAL FEATURES ASSOCIATED WITH VERNAL KERATOCONJUNCTIVITIS

A STUDY TO EVALUATE AND COMPARE THE EFFICACY AND SAFETY OF TOPICAL CYCLOSPORINE-A 0.5% WITH TOPICAL PLACEBO (ARTIFICIAL TEARS) IN ALLEVIATING THE CLINICAL FEATURES ASSOCIATED WITH VERNAL KERATOCONJUNCTIVITIS

Blog Article

Introduction: Vernal keratoconjunctivitis is a severe, typically seasonal recurrent ocular inflammatory disorder.Topical cyclosporine-A is inhibitory to many T-cell dependent inflammatory mechanisms which are likely to play role in click here treatment of vernal keratoconjunctivitis.Methodology: The study was conducted on 100 patients of vernal keratoconjunctivits selected from Ophthalmology out patients Department of Dr.D.

Y Patil Hospital, Pune.Patients were divided in two groups of 50 each, group I and group II.It was double masked comparison study to assess and compare the efficacy of 0.5% topical Cyclosporine-A and topical placebo in the treatment of vernal keratoconjunctivits.

Results: Comparing therapeutic response of symptoms in two groups at day 28 of the study shows topical cyclosporine was better and favored over placebo.Patients showed improvement in following symptoms accordingly.Itching: 49 in group I, 33 in group II.Discharge: 33 in group I, 4 in group II.

Photophobia: 32 in group I, 1 in group II.Foreign body sensation: 35 group I, 11 in group II.Patients showed improvement in following signs accordingly: Conjunctival inflammation: 40 in group I, 11 in group II.Papillary hypertrophy: 15 in nightstick twm-850xl group I, none in group II.

Limbal changes: 7 in group I, none in group II.Conclusion: The use of topical cyclosporine for treatment of vernal keratoconjunctivitis should be encouraged to prevent complications associated with the natural course of the disease and prolonged topical use of corticosteroids.